PDCD1 and hepatocellular carcinoma: Hence, we conducted this retrospective study to evaluate the incidence of HBVr and potential risk factors in patients with HBV-related hepatocellular carcinoma undergoing PD-1 inhibitors monotherapy or combination therapy and concurrent first-line antivirals.